[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-volunteers---male-and-female\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-volunteers---male-and-female":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,79,99,119,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100617355","phase-1-study-of-abs-201-evaluating-single-and-multiple-ascending-doses-in-healthy-adults-with-and-without-androgenetic-alopecia-100617355",false,"NCT07317544","Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia","A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Healthy Adult Participants With and Without Androgenetic Alopecia","Inclusion Criteria (Major):\n\n* Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG.\n* Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analysis parameters\n* Must have a body mass index (BMI) of 18 to 32 kg\u002Fm2, inclusive, at screening, with a total body weight \\>60 kg.\n* Participants, male and female, must be willing to avoid pregnancy for the duration of the trial.\n* Participants must be capable of giving signed informed consent\n* Participants must have no signs or symptoms of active or latent tuberculosis (TB),\n\nAdditional Inclusion criteria for patients with AGA:\n\n* Diagnosis of AGA with a Norwood-Hamilton Scale III vertex to V pattern.\n* Willing to clip target hair area for analysis and avoid scalp pigmentation products.\n* Willingness to maintain approximately the same hair length at each study visit\n* Additional Inclusion Criteria for postmenopausal women with AGA: Diagnosis of AGA with a Ludwig Scale I-3, I-4, II-1, II-2 pattern, with a documented history of AGA for ≥12 months and no rapid progression (e.g., sudden shedding, acute diffuse thinning, or scarring alopecia) in the 6 months prior to screening.\n\nExclusion Criteria (Major):\n\n* History or presence of cancer, except for basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for ≥90 days before screening.\n* History of liver disease, Gilbert's syndrome, or abnormal liver function tests (e.g., ALT, AST, or bilirubin \\> ULN) at screening\n* Systolic blood pressure ≤90 or ≥140 mmHg, diastolic BP ≤40 or ≥90 mmHg, pulse rate \\\u003C40 or \\>100 bpm\n* Positive test for HIV, hepatitis B (HBV), or hepatitis C (HCV).\n* Recent blood donation\n* Any clinically significant psychiatric disorder\n* Pregnant or breastfeeding females or those planning pregnancy during the study.\n* History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome\n\nAdditional Exclusion criteria for participants with AGA undergoing hair assessments:\n\n* Prior use of hair loss treatments:\n\n  1. Topical minoxidil within 3 months before screening.\n  2. Oral minoxidil other hair growth stimulators within 6 months before screening.\n  3. Finasteride within 6 months before screening\n  4. Dutasteride within 12 months before screening.\n* Use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or similar agents) within 3 months prior to screening\n* History of hair transplantation or other major scalp procedures or planned procedures during the study.\n* Use of hair extensions, wigs, hairpieces, weaves, or any other artificial hair enhancement methods within 30 days prior to screening and throughout the study.\n* History of clinically significant dermatologic disease of the scalp that could interfere with hair assessments or target area imaging",true,"ALL","18 Years","65 Years",{"count":21,"type":22},227,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The goal of this clinical trial is to learn if ABS-201 (a new medication) is safe and tolerable when used to improve hair growth in men and women. The trial will start with healthy volunteers and if safe, will treat participants with certain types of hair loss.\n\nThe main questions it aims to answer are:\n\nWhat medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication).\n\nParticipants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 1 year.",[29,30],"Androgenetic Alopecia (AGA)","Healthy Volunteers - Male and Female",[32,33,34,35,36,37],"Androgenetic Alopecia","Hair Loss","AGA","Female hair loss","Male pattern baldness","hair regrowth","RECRUITING","2026-05-19",{"date":41,"type":42},"2026-05-22","ACTUAL",{"date":44,"type":42},"2025-12-03",{"date":46,"type":22},"2028-07",{"name":48,"class":49},"Absci Pty Ltd.","INDUSTRY",4,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100616432","f-perfluoropropane-mri-100616432","NCT07305532","¹⁹F (Perfluoropropane) MRI","HARDWARE AND SOFTWARE DEVELOPMENT FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED INERT FLOURINATED GAS","Inclusion Criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.\n2. Provision of written, informed consent prior to any study specific procedures.\n3. Males and females aged 18 to 85 years.\n4. Participant must be able to perform a breath-hold for 16s.\n5. Participant has a BMI between 18 and 40\n6. Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)\n7. Participants are judged to be in stable health on the basis of medical history\n\nExclusion Criteria:\n\nParticipants fulfilling any of the following criteria are not eligible for inclusion in this study:\n\n1. Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist).\n2. In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.\n3. Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.\n4. Participant is unable to perform spirometry maneuvers.\n5. Participant is unable to perform MRI and CT breath-hold maneuvers.\n6. Participant has a history of chronic or acute respiratory disease\n7. FEV1 \\\u003C70%\n8. Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)\n9. Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine","85 Years",{"count":60,"type":22},200,[62],"NA","Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.",[30],[66],"19F(perfluoropropane) MRI","NOT_YET_RECRUITING","2026-04-16",{"date":70,"type":42},"2026-04-22",{"date":72,"type":22},"2026-05-20",{"date":74,"type":22},"2030-12-30",{"name":76,"class":77},"Alexei Ouriadov","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":78},"100633999","xexenon-mri-program-100633999","NCT07533981","¹²⁹Xe(XENON) MRI Program","HARDWARE AND SOFTWARE DEVELOPMENT FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED INERT HYPERPOLARIZED ¹²⁹XENON GAS","Inclusion Criteria:\n\n* Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.\n* Provision of written, informed consent prior to any study specific procedures.\n* Males and females aged 18 to 85 years.\n* Participant must be able to perform a breath-hold for 16s.\n* Participant has a BMI between 18 and 40\n* Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)\n* Participants are judged to be in stable health on the basis of medical history\n\nExclusion Criteria:\n\n* Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and\u002For ear implants) (at the discretion of the MRI Technologist).\n* In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.\n* Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.\n* Participant is unable to perform spirometry maneuvers.\n* Participant is unable to perform MRI and CT breath-hold maneuvers.\n* Participant has a history of chronic or acute respiratory disease\n* FEV1 \\\u003C70%\n* Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)\n* Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine",{"count":60,"type":22},[62],"Healthy volunteers aged 18 to 85 will undergo hyperpolarized Xenon-129 (¹²⁹Xe) MRI and pulmonary function testing. The study aims to develop evaluation tools for ventilation defect percent (VDP), signal-to-noise and contrast-to-noise ratios (SNR\u002FCNR) of ¹²⁹Xe dissolved-phase images, and spectroscopy-based analysis.",[30],[91],"129 Xe MRI","2026-04-13",{"date":68,"type":42},{"date":95,"type":22},"2026-07-01",{"date":97,"type":22},"2031-04-30",{"name":76,"class":77},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":78},"100626758","phase-1-a-study-of-orn252-in-healthy-participants-100626758","NCT07439796","A Study of ORN252 in Healthy Participants","A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORN252 in Healthy Participants","Inclusion Criteria:\n\n* Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests\n* Participant is willing and able to comply with study visits and other protocol requirements\n* Other protocol specific inclusion criteria may apply\n\nExclusion Criteria:\n\n* Clinically significant history or presence of organ dysfunction\n* Use of any investigational product within 3 months, or 5 half-lives, whichever longer\n* Other protocol specific exclusion criteria may apply","55 Years",{"count":108,"type":22},20,[25],"The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.",[30],{"date":68,"type":42},{"date":114,"type":42},"2026-03-16",{"date":116,"type":22},"2027-03",{"name":118,"class":49},"Orna Therapeutics, Inc.",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100617017","phase-1-a-phase-i-trial-of-subcutaneous-qls7305-in-healthy-adults-100617017","NCT07313150","A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of QLS7305 Following Subcutaneous Administration in Healthy Chinese Participants.","Inclusion Criteria:\n\nAged between 18 and 55 years (inclusive) Physical examination, vital signs, laboratory tests, 12-lead ECG, and imaging findings are within normal ranges.\n\nBody weight ≥50 kg for males and ≥45 kg for females, with a BM) between 18.0 and 28 kg\u002Fm² (inclusive).\n\nWilling or has complied with the administration of meningococcal and pneumococcal vaccines as required by the protocol.\n\nNo plan to donate sperm or ova, no pregnancy plan, and voluntarily agrees to use effective contraception methods from the signing of the ICF until 12 months after administration of the investigational product.\n\nAble to understand and comply with the study procedures, voluntarily participate in the trial, and provide written informed consent.\n\nExclusion Criteria:\n\nHistory of food or drug allergy, and\u002For known allergy to GalNAc. History of definite infection with encapsulated bacteria within 6 months prior to screening.\n\nHistory of recurrent or chronic infection within 3 months prior to screening. Presence or suspicion of active viral, bacterial, fungal, or parasitic infection within 1 month prior to baseline.\n\nAny disease at screening that, in the investigator's judgment, could affect the study data.\n\nHistory of malignancy. Any condition that may affect drug absorption. History of splenectomy or congenital asplenia. History of congenital or acquired complement deficiency or disorder. History of allergic diseases (e.g., allergic asthma, allergic rhinitis).",{"count":127,"type":22},60,[25],"The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China. The main questions it aims to answer are:\n\nWhat is the safety and tolerability profile of single and multiple subcutaneous doses of QLS7305 in healthy adults? What are the pharmacokinetic (PK) characteristics of QLS7305 and its major metabolites? What are the pharmacodynamic (PD) effects of QLS7305 on the complement system (e.g., serum C3 levels and complement activity)? Does QLS7305 induce an immunogenic response (anti-drug antibodies)? What is the effect of QLS7305 on the QTc interval? Investigators will compare different dose levels of QLS7305 to a placebo group to see the effects on safety, tolerability, and the measured parameters.\n\nParticipants will:\n\nBe enrolled in one of two parts of the study:\n\nPart A (Single Ascending Dose): Receive a single dose of QLS7305 or placebo. Part B (Multiple Ascending Dose): Receive multiple doses of QLS7305 or placebo (doses selected based on Part A results).\n\nReceive prophylactic antibiotics (Penicillin V) after the first dose until their serum complement C3 level recovers, as a safety precaution.\n\nUndergo close safety monitoring throughout the study, including a follow-up period of up to 337 days to ensure safety parameters return to acceptable levels.",[30],[132,133,134,135,136,137],"QLS7305","Double-stranded small interfering ribonucleic acid (siRNA) targeting complement","First-in-human","C3","SAD","MAD","2025-12-22",{"date":140,"type":42},"2025-12-31",{"date":142,"type":22},"2026-01",{"date":144,"type":22},"2027-12",{"name":146,"class":49},"Qilu Pharmaceutical Co., Ltd.",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":78},"100607030","resting-state-imaging-and-chronic-consumption-of-non-nutritive-sweeteners-100607030","NCT07183254","Resting-state Imaging and Chronic Consumption of Non-Nutritive SweetenerS","Resting-state Functional Imaging in Chronic Consumption of Non-energetic Artificial Sweeteners","RNSS","Inclusion Criteria:\n\n* Men and women aged 18 to 30 (and in good health)\n* Having low or no sweetener consumption (\\~8 mg ± 5.05 mg\u002Fday) or high consumption (\\~80 mg ± 91.72 mg\u002Fday)\n* Having a BMI of 18.5 \\\u003C 24.9\n* For young women: having effective contraception maintained throughout the study\n* Able to give informed consent to participate in the research\n* Affiliation to a Social Security scheme\n\nExclusion Criteria:\n\n* Refusing to participate in the research\n* With impaired understanding, according to the investigator\n* Volunteer under guardianship\u002Fcuratorship\u002Fdeprived of liberty or under legal protection\n* Incompatibility of healthy volunteers with the medical imaging center's safety criteria for conducting 3 Tesla MRI experiments\n* Presenting \"contraindications\" to an MRI examination without injection: presence of metal parts in the body (electronic devices such as a pacemaker, a neurostimulator, cochlear implant, prostheses, intraocular foreign bodies, etc.), claustrophobia, obesity\n* Refusal to be informed in the event of an incidental discovery of an abnormality on MRI\n* Volunteer with neurological disease, psychiatric or behavioral disorders\\*\n* Volunteer with addiction\\*:\n\n  * Nicotine: smoker or former smoker of less than 12 months;\n  * Alcoholism - \"AUDIT\" test: Female score ≥ 6 and male score ≥ 7;\n  * Drugs - \"DAST-10\": Score ≥ 1;\n  * Gambling - \"ICJE\": Score ≥ 3\n  * Video games - Modified DSM IV Video Game Addiction Test: More than 4 positive responses. - Positive urine drug screen\n* Volunteer with an eating disorder (ED)\\*:\n\n  o Eating disorder - \"SCOFF\": At least two positive responses. - Volunteers with at least one chronic condition (obesity, diabetes, cardiovascular, renal, or hepatic diseases, etc.)\\*\n* Pregnant or breastfeeding women, or healthy subjects wishing to conceive during the current study year\\*\n* Any illness, health condition, or history deemed incompatible with the trial by the investigator\n* Volunteers following a specific or highly restrictive diet (vegetarians, vegans, or vegans; multiple dietary exclusions related to religion, food allergies or intolerances; diets related to intensive exercise or weight-loss)\\*\n* Currently excluded from another study\n* Currently participating in another clinical trial, or in the exclusion period, or having received a total compensation amount exceeding €6,000 in the 12 months preceding the start of the trial,\n\n  * This study is part of a larger research project, also involving cognitive tasks and the measurement of food preferences. These exclusion criteria were therefore added in order to standardize the profile of the participants.","30 Years",{"count":157,"type":22},100,[62],"Non-nutritive sweeteners are used as a substitute for simple sugars to improve the palatability of food products without increasing their sugar and calorie content. They represent a global market of 7 billion euros, with an annual growth of 5%. Reducing their consumption therefore seems to be excluded. Some studies have focused on the impacts of these substances on brain activity. According to a recent study, continuous consumption of low doses of saccharin in adult mice significantly decreases the level of dopamine in the prefrontal cortex and significantly increases striatal dopamine, which modifies decision-making strategies. Resting-state functional Magnetic Resonance Imaging (r-fMRI) studies in humans have also shown that an increase in striatal dopaminergic activity modifies the resting-state functional connectivity of brain regions linked to the reward circuit. r-fMRI allows the characterization of brain networks and the strength of correlations between brain regions, without any specific task being required. It is a rapid, non-invasive technique that can measure changes in brain functional connectivity.\n\nIn addition to r-fMRI, diffusion tensor imaging (DTI) is able to assess white matter microstructure and the integrity or otherwise of fiber tracts. Several parameters such as the fractional anisotropy (FA), coefficient of white matter, mean diffusivity, and radial diffusivity can be modified in the event of changes in functional connectivity, reflecting axonal rearrangements, not visible on conventional MRI sequences. Based on previous research, investigators hypothesize that (1) chronic consumption of non-nutritive artificial sweeteners increases striatal dopaminergic activity. (2) This modification is accompanied by changes in resting-state functional connectivity in brain regions of interest associated with the reward circuit in healthy young adults.\n\nThen, the primary objective of this study is to compare, in the resting state, the differences in functional connectivity of brain regions of interest between \"non\u002Flow consumers\" and \"high consumers\" of sweeteners at the start of the study using r-fMRI.\n\nThe key secondary objective of this study is to assess changes in brain connectivity using r-fMRI in non- and low-consuming subjects before and after a transient increase in their sweetener consumption over 5 weeks.\n\nThe secondary objectives include assessing daily sugar consumption (5-week follow-up), daily consumption of non-energy-rich artificial sweeteners (5-week follow-up), Body Mass Index (BMI), physical activity level, and white matter microstructure and fibrous tract integrity using a diffusion-weighted MRI (DTI) sequence.",[30],[162,163,164,165,166,167,168],"non-nutritive sweeteners","non- and low consumers","high consumers","resting-state MRI","diffusion tensor imaging (DTI)","reward circuit","resting-state functional connectivity","2025-09-18",{"date":171,"type":42},"2025-09-19",{"date":173,"type":22},"2025-10-01",{"date":175,"type":22},"2027-12-01",{"name":177,"class":77},"University Hospital, Clermont-Ferrand"]